76 related articles for article (PubMed ID: 24377315)
1. Comparison of cancer cell survival triggered by microtubule damage after turning Dyrk1B kinase on and off.
Li L; Liu Y; Zhang Q; Zhou H; Zhang Y; Yan B
ACS Chem Biol; 2014 Mar; 9(3):731-42. PubMed ID: 24377315
[TBL] [Abstract][Full Text] [Related]
2. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
[TBL] [Abstract][Full Text] [Related]
3. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
[TBL] [Abstract][Full Text] [Related]
4. How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Szamborska-Gbur A; Rutkowska E; Dreas A; Frid M; Vilenchik M; Milik M; Brzózka K; Król M
J Mol Model; 2019 Jan; 25(2):41. PubMed ID: 30673861
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
Kettle JG; Ballard P; Bardelle C; Cockerill M; Colclough N; Critchlow SE; Debreczeni J; Fairley G; Fillery S; Graham MA; Goodwin L; Guichard S; Hudson K; Ward RA; Whittaker D
J Med Chem; 2015 Mar; 58(6):2834-44. PubMed ID: 25738750
[TBL] [Abstract][Full Text] [Related]
6. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
[TBL] [Abstract][Full Text] [Related]
7. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.
Qiao F; Zuo D; Shen X; Qi H; Wang H; Zhang W; Wu Y
Cancer Chemother Pharmacol; 2012 Aug; 70(2):259-70. PubMed ID: 22752214
[TBL] [Abstract][Full Text] [Related]
8. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
9. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway.
Facchinetti MM; De Siervi A; Toskos D; Senderowicz AM
Cancer Res; 2004 May; 64(10):3629-37. PubMed ID: 15150122
[TBL] [Abstract][Full Text] [Related]
10. Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors.
Hoque M; Abbassi RH; Froio D; Man J; Johns TG; Stringer BW; Day BW; Pajic M; Kassiou M; Munoz L
Pharmacol Res; 2018 Aug; 134():166-178. PubMed ID: 29944980
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
Hu J; Deng H; Friedman EA
Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
[TBL] [Abstract][Full Text] [Related]
13. PMA synergistically enhances apicularen A-induced cytotoxicity by disrupting microtubule networks in HeLa cells.
Seo KS; Kim JS; Park JH; Song KS; Yun EJ; Park JI; Kweon GR; Yoon WH; Lim K; Hwang BD
BMC Cancer; 2014 Jan; 14():36. PubMed ID: 24447339
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis through tubulin inhibition in human cancer cells by new chromene-based chalcones.
Aryapour H; Riazi GH; Ahmadian S; Foroumadi A; Mahdavi M; Emami S
Pharm Biol; 2012 Dec; 50(12):1551-60. PubMed ID: 22984888
[TBL] [Abstract][Full Text] [Related]
15. A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.
Becker W
FEBS J; 2018 Apr; 285(7):1203-1211. PubMed ID: 29193696
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of the antitumor activity of SB225002: a novel microtubule inhibitor.
Goda AE; Koyama M; Sowa Y; Elokely KM; Yoshida T; Kim BY; Sakai T
Biochem Pharmacol; 2013 Jun; 85(12):1741-52. PubMed ID: 23611835
[TBL] [Abstract][Full Text] [Related]
17. Mycotoxin citrinin induced cell cycle G2/M arrest and numerical chromosomal aberration associated with disruption of microtubule formation in human cells.
Chang CH; Yu FY; Wu TS; Wang LT; Liu BH
Toxicol Sci; 2011 Jan; 119(1):84-92. PubMed ID: 20929984
[TBL] [Abstract][Full Text] [Related]
18. XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro.
Wu R; Ding W; Liu T; Zhu H; Hu Y; Yang B; He Q
Cancer Lett; 2009 Nov; 285(1):13-22. PubMed ID: 19647933
[TBL] [Abstract][Full Text] [Related]
19. Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells.
Wu X; Sooman L; Lennartsson J; Bergström S; Bergqvist M; Gullbo J; Ekman S
Int J Oncol; 2013 Jan; 42(1):297-304. PubMed ID: 23174948
[TBL] [Abstract][Full Text] [Related]
20. Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors.
Tanabe K
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29168788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
